Other examples include acquired mutations in the kinase domain of BCR-ABL1 in chronic myelogenous leukemia patients treated with imatinib [3] and secondary mutations in epidermal growth factor receptor in nonsmall-cell lung cancer patients treated with selective epidermal growth factor receptor inhibitors such as gefitinib [4]. This evidence concerns the gene EGFR and lung cancer.